Animal efficacy study of a plant extract complex (BEN815) as a potential treatment for COVID-19

In a short time, several types of injectable and oral therapeutics have been developed and used to effectively manage patients with coronavirus disease 2019 (COVID-19). BEN815 is an improved mixture of three extracts (Psidium guajava, Camellia sinensis, and Rosa hybrida) recognized by the Ministry o...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-09, Vol.18 (9), p.e0291537
Main Authors: Do, Moon Ho, Li, Hua, Cho, Su Yeon, Oh, Subin, Jeong, Ju Hwan, Song, Min-Suk, Jeong, Jong-Moon
Format: Article
Language:English
Subjects:
Allergic rhinitis
Animal tissues
Animals
Animals, Laboratory
Antiviral drugs
Biology and life sciences
Camellia sinensis
Catechin
Coronaviruses
COVID-19
Cytokines
Effectiveness
Food
Food allergies
Genetic engineering
Health aspects
Health services
Infection
Infections
Lungs
Medical treatment
Medicine and health sciences
Mice
Mice, Transgenic
Natural & organic foods
Pandemics
Pharmacovigilance
Plant extracts
Plant Extracts - pharmacology
Plant Extracts - therapeutic use
Proteins
Research and Analysis Methods
Rhinitis
RNA polymerase
Safety and security measures
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Signs and symptoms
Statistical significance
Tea
Transgenic mice
Variance analysis
Viral diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a short time, several types of injectable and oral therapeutics have been developed and used to effectively manage patients with coronavirus disease 2019 (COVID-19). BEN815 is an improved mixture of three extracts (Psidium guajava, Camellia sinensis, and Rosa hybrida) recognized by the Ministry of Food and Drug Safety of Korea as a health food ingredient that alleviates allergic rhinitis. The current animal efficacy study was performed to assess its probability of improving COVID-19 symptoms. BEN815 treatment significantly increased the survival of K18-hACE2 transgenic mice and reduced viral titers in the lungs at 5 days post infection (DPI). Furthermore, the lungs of the treated mice showed mild tissue damage at 5 DPI and nearly complete recovery from COVID-19 at 14 DPI. BEN815 appears to be an effective and minimally toxic anti-SARS-CoV-2 agent in mice and has potential for clinical applications.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0291537